In this episode, Dr. Renee Rogers joins Dr. Lou Atkinson to explore the evolving impact of GLP-1s , not just on weight loss, but on the systems that surround it: research, muscle health, behaviour change, and stigma.They explore how the rise of GLP-1s is reshaping expectations in the fitness and wellness space , and why many current responses risk missing the mark. From resistance training prescriptions to protein pushes, there’s a gap between what’s being offered and what people actually need. Together, they discuss how new research is shifting focus from surface-level outcomes to what really matters: lived experience, muscle quality, sustainable behaviour change, and personalised long-term support.It’s a conversation about human-centred design in a market chasing quick fixes. Because people don’t just need new medications, they need new mindsets.💡 As McKinsey noted in The $2 Trillion Global Wellness Market Gets a Millennial and Gen Z Glow-Up (May 2025), over a third of Gen Z and millennials in the US and UK say managing their weight is “very difficult.” With GLP-1s accelerating momentum, the real opportunity isn’t in the drugs , it’s in what we build around them.📄 Don’t forget to check out our white paper for a deeper dive: Supporting the GLP-1 Consumer Beyond the Prescription.Too many GLP-1 users face stigma not only for their weight, but for choosing evidence-based medical care. In a world where even high performers are chained to their desks for 8+ hours a day, we can’t out-exercise the systems we live in. It’s time to stop blaming individuals and start designing better support.https://www.wearethecollective.world/tools-to-transformShout Outs:Katherine Saunders, MDChapters00:00 Introduction to GLP-1 Agonist Medications03:12 Renee Rogers' Journey and Background05:50 Understanding GLP-1 Medications: History and Development11:56 The Evolving Landscape of Obesity Treatment14:49 Personalised Approaches to Obesity Management17:44 Research Insights on Lifestyle Modifications24:07 Behavioural Insights and Patient Experiences27:57 Market Opportunities in the GLP-1 Space31:58 Understanding Consumer Behaviour in Health Supplements34:40 The Importance of Language in Health Claims36:51 Shifting the Focus from Weight to Well-being39:56 Personalisation in Health and Fitness Programs43:13 The Role of Relevance in Behaviour Change48:34 Exploring GLP-1 Medications and Preventive Health55:28 Navigating the Wild West of Health Interventions58:56 Advocating for Access and Equity in HealthcareShout Outs:Katherine Saunders, MDChapters00:00 Introduction to GLP-1 Agonist Medications03:12 Renee Rogers' Journey and Background05:50 Understanding GLP-1 Medications: History and Development11:56 The Evolving Landscape of Obesity Treatment14:49 Personalised Approaches to Obesity Management17:44 Research Insights on Lifestyle Modifications24:07 Behavioural Insights and Patient Experiences27:57 Market Opportunities in the GLP-1 Space31:58 Understanding Consumer Behaviour in Health Supplements34:40 The Importance of Language in Health Claims36:51 Shifting the Focus from Weight to Well-being39:56 Personalisation in Health and Fitness Programs43:13 The Role of Relevance in Behaviour Change48:34 Exploring GLP-1 Medications and Preventive Health55:28 Navigating the Wild West of Health Interventions58:56 Advocating for Access and Equity in Healthcare

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related